CROI 2019 Program and Conference Information

Oral Sessions

135 11:15

CHARACTERIZING THE PROVIRAL LANDSCAPE INHIV-1 ELITE CONTROLLERS Chenyang Jiang, Xiaodong Lian, Joshua Chevalier, Samantha M. Chen, Ce Gao, Xiaoming Sun, Kevin Einkauf, Ben S. Rhee, Kaylee Chang, Jane Blackmer, Bruce D. Walker, Mathias Lichterfeld, Xu G. Yu INTERFERON Α2B REDUCES INDUCIBLE CD4-ASSOCIATED HIV IN ART-SUPPRESSED INDIVIDUALS Livio Azzoni, Emmanouil Papasavvas, Jay Kostman, Pablo Tebas, Karam Mounzer, Ian Frank, Kenneth M. Lynn, Linden Lalley-Chareczko, Rui Feng, Scott Appel, Bonnie J. Howell, Daniel Holder, Shih Lin Goh, Guoxin Wu, Luis Montaner NEF-STOP REPAIR DYNAMICS, BUT NOT ANTI-Α4Β7, INFLUENCE POSTTREATMENT VIRAL CONTROL Michele Di Mascio, Sharat Srinivasula, Paula DeGrange, Brandon F. Keele, Michael Proschan, Jeffrey D. Lifson, H. Clifford Lane

136 11:30

137 11:45

Oral Abstract O-13 ANTIRETROVIRAL CLINICAL TRIALS AND RESISTANCE Room 6AB

10:00 AM - 12:00 PM

Oral Abstract Moderators Sharon Riddler, University of Pittsburgh, Pittsburgh, PA, USA Johnstone Kumwenda, College of Medicine-Johns Hopkins Project, Blantyre, Malawi 138

SEARCH INTERVENTION REDUCESMORTALITY AT A POPULATION LEVEL INMENWITH LOWCD4 COUNT Moses R. Kamya, Maya L. Petersen, Dalsone Kwariisima, James Ayieko, Norton Sang, Jane Kabami, Tamara D. Clark, Edwin D. Charlebois, Laura B. Balzer, Craig R. Cohen, Vivek Jain, Elizabeth A. Bukusi, Gabriel Chamie, Diane V. Havlir LONG-ACTING CABOTEGRAVIR+RILPIVIRINE ASMAINTENANCE THERAPY: ATLASWEEK 48 RESULTS Susan Swindells, Jaime-Federico Andrade-Villanueva, Gary J. Richmond, Giuliano Rizzardini, Axel Baumgarten, Maria Del Mar Masia, Gulam Latiff, Vadim Pokrovsky, Joseph M. Mrus, Jenny O. Huang, Krischan J. Hudson, David A. Margolis, Kimberly Smith, Peter E. Williams, William Spreen Chloe Orkin, Keikawus Arastéh, Miguel Górgolas Hernández-Mora, Vadim Pokrovsky, Edgar T. Overton, Pierre-Marie Girard, Shinichi Oka, Ronald D’Amico, David Dorey, Sandy Griffith, David A. Margolis, Peter E. Williams, Wim Parys, William Spreen SAFETY AND PK OF SUBCUTANEOUS GS-6207, A NOVEL HIV-1 CAPSID INHIBITOR Jennifer E. Sager, Rebecca Begley, Martin Rhee, Steve K. West, John Ling, Scott D. Schroeder, Winston C. Tse, Anita Mathias A PHASE IIA STUDY OF NOVEL MATURATION INHIBITOR GSK2838232 INHIV PATIENTS Edwin DeJesus, Sara Harward, Roxanne C. Jewell, Mark Johnson, Etienne Dumont, Viviana Wilches, Fiona Halliday, Christine Talarico, Jerry Jeffrey, Kevin Gan, Franco B. Felizarta, Anita Scribner, Moti Ramgopal, Paul Benson, Brian A. Johns

10:00

139 10:15

140 LB LONG-ACTING CABOTEGRAVIR+RILPIVIRINE FOR HIV MAINTENANCE: FLAIRWEEK 48 RESULTS 10:30

141 10:45

142 11:00

Oral Sessions • Thursday

CROI 2019 55